Mode
Text Size
Log in / Sign up

Expert panel agrees on early detection and ARPI/ADT role for high-risk prostate cancer BCR

Expert panel agrees on early detection and ARPI/ADT role for high-risk prostate cancer BCR
Photo by Graham Ruttan / Unsplash
Key Takeaway
Note: Expert opinions on BCR management agree on early detection and ARPI/ADT role but lack consensus on timing and resources.

An expert opinion review summarized discussions from a panel focused on managing high-risk biochemical recurrence in prostate cancer following primary therapy. The panel composition, specific patient population details, and study methodology were not reported. The review did not evaluate a specific intervention or comparator but focused on synthesizing expert perspectives on clinical management approaches.

The panel reached agreement on several key topics: the importance of early detection of high-risk biochemical recurrence, the need for risk stratification, the value of early management, and the role of androgen receptor signaling pathway inhibitors and androgen deprivation therapies. However, the panel lacked agreement on two critical practical issues: the optimal timing for intervention and strategies for resource allocation. No specific data, effect sizes, or statistical measures supporting these opinions were provided.

No safety or tolerability information was reported, as the review did not analyze treatment outcomes. The primary limitation noted was the lack of consensus on timing and resource allocation, which are essential for clinical decision-making. The funding sources and potential conflicts of interest were not reported.

For practice, the review suggests that multidisciplinary approaches may facilitate personalized treatment planning for high-risk biochemical recurrence. However, clinicians should recognize this represents expert opinion without supporting clinical trial data. The authors explicitly state further research is warranted to refine predictive models, optimize resource allocation, and enhance therapeutic efficacy before these opinions can translate into standardized protocols.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
PurposeBiochemical recurrence (BCR) following primary therapy for prostate cancer (PCa) is associated with disease progression; thus, identifying patients at high risk and implementing management strategies remains critical. This expert opinion outlines a set of recommendations for identifying high-risk BCR patients, provides insights into the impact of a multidisciplinary team (MDT) approach on disease management, explores associated costs and resource utilization, and examines the role of androgen receptor signaling pathway inhibitors (ARPIs) in optimizing outcomes.MethodsThe latest evidence and clinical guidelines on risk stratification, diagnostic tools, and collaborative management strategies were evaluated. Additionally, expert opinions were collected from nine oncology and urology experts, and their insights were integrated to form a comprehensive approach tailored for clinical application.ResultsThe panelists reached agreement on several proposed questions, including patients’ early detection, risk stratification, early management, and the role of ARPIs and androgen deprivation therapies (ADT). The recommendations emphasize the need for standardized identification of high-risk BCR patients, treatment protocols, and early intervention strategies. Additionally, the multidisciplinary approach facilitates personalized treatment planning, leveraging various specialties’ expertise, and addresses the complexity of resource utilization and cost management. However, a lack of agreement on other topics was observed, such as optimal timing of intervention and resource allocation strategies.ConclusionThis narrative, evidence-supported expert-opinion review highlights the importance of standardized protocols, multidisciplinary strategies, and the integration of advanced diagnostics and androgen receptor pathway inhibitors to improve patient outcomes. Further research is warranted to refine predictive models, optimize resource allocation, and enhance therapeutic efficacy.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.